最新ニュース NovoCure (NASDAQ:NVCR) 株価情報

NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

News

UHAL

Reported Sunday, U-Haul Adds Climate-Controlled Storage Units In Marietta With New Two-Story Facility

Customers in the U.S. looking to purchase an electric vehicle can get a $7500 federal EV tax credit for several models including from Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), and more. However, President Donald Trump on Monday said that his administration would consider ending tax credits, impacting the purchase price for eligible customers.
Vehicles That Qualify: The various Tesla electric vehicles eligible for $7,500 include select trims of the Cybertruck, Model 3, Model X, and Model Y. Other brand vehicles that qualify include the Kia EV9 and selected trims of the F-150 Lightning truck.
The only Plug-in Hybrid that qualifies for the credit is the Chrysler Pacifica PHEV.
The list of vehicles that qualify for the tax credit right now is as follows:
<ul>
<li>Acura ZDX</li>
<li>Cadillac Lyriq (Luxury and Sport Models)</li>
<li>Cadillac Optiq</li>
<li>Chevrolet Blazer EV (LT, RS, and SS Models)</li>
<li>Chevrolet Equinox EV (LT and RS Models)</li>
<li>Chevrolet Silverado EV (LT Model)</li>
<li>Ford F-150 Lightning (Flash, Lariat and XLT Trims)</li>
<li>Honda Prologue</li>
<li>Jeep Wagoneer S</li>
<li>Kia EV6</li>
<li>Kia EV9</li>
<li>Tesla Cybertruck (Single Motor and Dual Motor)</li>
<li>Tesla Model 3 (Long Range AWD, Long Range RWD, Performance variants)</li>
<li>Tesla Model X (AWD Variant)</li>
<li>Tesla Model Y (Long Range AWD, Long Range RWD, Performance variants)</li>
<li>Chrysler Pacifica PHEV</li>
</ul>
Trump&#8217;s Take On EV Tax Credits: In November, Reuters reported that Donald Trump‘s transition team plans to kill the $7,500 tax credit available on EV purchases. On Monday, after his inauguration, Trump himself said his administration would consider ending EV tax credits.
&#8220;The Republicans have a very small majority in the House, which could make it hard for the party to pass legislation of any kind,&#8221; The Future Fund Managing Partner Gary Black said about a possible repeal of the tax credit on Monday. &#8220;Another wild card is Elon Musk, with $TSLA accounting for nearly half of all EVs sold in the country. With Elon Musk close to the president, it is important to know how he will seek to shape changes to the tax credit. Other auto executives have also been lobbying Mr. Trump against a repeal of the credit. Among them is Ford's executive chairman, William C. Ford Jr., who recently spoke to the president-elect.&#8221;
However, Tesla CEO Elon Musk, a close Trump ally, has previously supported scrapping of the tax credit. 
"In my view, we should end all government subsidies, including those for EVs, oil and gas," Musk said in November.
During Tesla&#8217;s second-quarter earnings in late July, Musk also said that the impact of the elimination of subsidies&nbsp;<a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably" target="_blank" rel="noreferrer noopener">would only be slight for Tesla</a>&nbsp;but devastating for its competitors. The elimination of EV subsidies would probably help Tesla in the long term, he added.
However, not all are in agreement. Tesla researcher Troy Teslike has previously said that the loss of tax credit will only make Tesla<a href="https://www.benzinga.com/24/12/42641207/researcher-says-cancelation-of-7500-ev-tax-credit-could-impact-teslas-deliveries-despite-ceo-elon-musk-claiming-otherwise" target="_blank" rel="noreferrer noopener">&nbsp;lose its market to gas cars</a>&nbsp;from luxury car brands.
Trump, on Monday also revoked a 2021 executive order signed by former President Joe Biden that sought to ensure that 50% of new vehicles sold in the U.S. by 2020 are electric.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43080738/nhtsa-opens-probe-into-about-878000-gm-gas-vehicles-days-after-closing-investigation-into-its-cruise-avs" target="_blank" rel="noreferrer noopener">NHTSA Opens Probe Into Nearly 878,000 GM Vehicles Over Engine Failure Concerns Days After Closing Investigation Into Its Cruise AVs</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Here Are The EVs Which Could Lose $7,500 EV Tax Credit Under Trump Administration

Amcon Distributing (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DIT#AMEX">DIT</a>) reported quarterly earnings of $0.57 per share. This is a 67.98 percent decrease over earnings of $1.78 per share from the same period last year. The company reported $711.27 million in sales this quarter. This is a 10.28 percent increase over sales of $644.96 million the same period last year.

Earnings

Reported Monday, Amcon Distributing Q1 EPS $0.57 Down From $1.78 YoY, Sales $711.27M Up From $644.96M YoY

<ul>
<li>Significant portfolio expansion to include combat-proven autonomous airborne platforms in support of critical forward-looking national security mission needs</li>
<li>Expected to be immediately accretive to Revenue, Adjusted EBITDA and Free Cash Flow</li>
<li>Post-transaction, Redwire expects to have a strong balance sheet</li>
</ul>

Reported Sunday, Redwire To Acquire Edge Autonomy In $925M Deal, Transforming Into A Multi-Domain Space And Defense Leader

Collaboration will bring bespoke content and never-before-seen show integrations

Reported Sunday, BetMGM Secures Online Casino Rights For Fremantle's "Family Feud" And "The Price Is Right"

Programming Already Restored for Two Million Viewers, Including NFL Playoff Games and Local News

ATUS

NXST

Reported Saturday, Nexstar And Optimum Reach Agreement To Restore Programming For Two Million Customers

<a href="https://www.globenewswire.com/Tracker?data=ZJKetO8zE3erzqRGF_P7-sCgwYhySBueJMgNqynfM3aNltyVHIqgYbS_u8Uz3Nv7SKdETdCLI16Ppo7Wvc4v8A==">NANOBIOTIX</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (<a href="https://www.globenewswire.com/Tracker?data=9AF1jPR-HWZ8jVuLKKF7MX10tUChZ_X2NGuXvAVUyFwhfw23CgjxX9aY63wN0Kdaec4QfEQsIuazNYZjxTvGX2JHp8IO-l0T8OXn7FrEKgkLxinTtGOoP8RlFCRY0HK-ieJqCKDibtD2Daq_RvrOBA==">NCT06667908</a>). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson &amp; Johnson Company, under a global license agreement.

NBTX

Nanobiotix Begins Phase 2 Trial for Innovative Cancer Treatment in Stage 3 Lung Cancer

ARBK

Argo Blockchain CEO Thomas Chippas To Exit; CFO Jim MacCallum Appointed As Interim Successor

The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/SCHW/earnings">opening bell, on Tuesday, Jan. 21, 2025.</a>
Analysts expect the Westlake, Texas-based company to report quarterly earnings at 91 cents per share, up from 68 cents per share in the year-ago period. Charles Schwab projects quarterly revenue of $5.2 billion, compared to $4.46 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 13, Charles Schwab said it expects FY24 net revenue to grow by 3.0%-3.5% versus the prior year.
Charles Schwab shares gained 1.2% to close at $76.41 on Friday&nbsp;&nbsp;&nbsp; .
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Wells Fargo analyst Michael Brown maintained an Equal-Weight rating and cut the price target from $90 to $89 on Jan. 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Christopher Allen maintained a Neutral rating and cut the price target from $85 to $80 on Jan. 10, 2025. This analyst has an accuracy rate of 77%.</li>
<li>JP Morgan analyst Kenneth Worthington maintained an Overweight rating and raised the price target from $87 to $93 on Jan. 7, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Piper Sandler analyst Patrick Moley maintained a Neutral rating and raised the price target from $65 to $70 on Jan. 7, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintained an Outperform rating and raised the price target from $81 to $93 on Dec. 20, 2024. This analyst has an accuracy rate of 65%.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png" alt="" class="wp-image-741030" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/20040940/image-124.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43054647/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

SCHW

Charles Schwab Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

GOEV

Reported Friday, Canoo Announces Chapter 7 Bankruptcy Filing, Ending Operations Effective Immediately

SPPL

Reported Friday, SIMPPLE Receives Nasdaq Notifications For Minimum Equity And Annual Meeting Deficiencies

Macro Economic Events

Econ #s

Economics

U.K. Unemployment Rate For November 4.4% Vs. 4.3% Est.; 4.3% Prior

U.K. Employment Change 3M/3M (MoM) For November 35K Vs. 35K Est.; 173K Prior

U.K. Claimant Count Change For December 0.7K Vs. 10.3K Est.; -25.1K (Revised) Prior

U.K. Average Earnings Index +Bonus For November 5.6% Vs. 5.6% Est.; 5.2% Prior

<ul>
<li>Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function</li>
<li>The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity</li>
<li>More than 800 million people have Chronic Kidney Disease (CKD), one of the world's leading causes of mortality worldwide, with associated deaths increasing over the past two decades1</li>
</ul>

VATE

Reported Friday, INNOVATE Announces FDA Approval Of MediBeacon's TGFR System For Accurate Kidney Function Testing

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares dropped 2.35% in overnight trading on Robinhood Markets on Tuesday, falling to $386.80 as cryptocurrency markets reacted to President Donald Trump&#8216;s inauguration speech that notably <a href="https://www.benzinga.com/25/01/43086698/crypto-market-plunges-after-trumps-inaugural-speech-fails-to-mention-digital-assets">omitted any mention of digital assets</a>.
What Happened: The enterprise software company, which holds over $45 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), had seen its stock surge 8.04% to $396.50 on Friday amid optimism about Trump&#8217;s anticipated crypto-friendly policies. 
The company&#8217;s executive chairman Michael Saylor attended a &#8220;Crypto Ball&#8221; last Friday where he met with Trump&#8217;s incoming cabinet members, fueling speculation about <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43078515/michael-saylor-meets-trumps-cabinet-at-crypto-ball-what-does-the-bitcoin-bulls-cryptic-post-indicate">favorable cryptocurrency regulations</a>.
However, Trump&#8217;s inaugural address focused instead on traditional assets, declaring the start of a &#8220;Golden Age of America&#8221; &#8211; a reference that prompted Bitcoin critic Peter Schiff to highlight the president&#8217;s apparent preference for gold over cryptocurrency. 
See Also: <a href="https://www.benzinga.com/25/01/43088034/bitcoin-ethereum-dogecoin-retrace-from-pre-inauguration-highs-as-trumps-address-disappoints-analyst-highlights-possibility-of-btc-consolidation-in-101k-106k-range">Bitcoin, Ethereum, Dogecoin Retrace From Pre-Inauguration Highs As Trump Skips Crypto Mention: Analyst Highlights BTC Consolidation In $101K-$106K Range</a>
Why It Matters: The speech&#8217;s omission of digital assets triggered a broader <a href="https://www.benzinga.com/25/01/43088563/bitcoin-vs-gold-peter-schiff-decodes-trumps-golden-age-reference-in-inaugural-speech">crypto market decline</a>, with Bitcoin falling from $106,000 to $101,775.
The selloff comes as Trump named Mark Uyeda as acting U.S. Securities and Exchange Commission chair, replacing Gary Gensler. 
The firm has been purchasing Bitcoin for ten consecutive weeks, according to its public disclosures.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43088840/donald-and-melania-trump-memecoins-crash-after-presidential-inaugurationfirst-couples-crypto-wealth-plunges-36">Donald And Melania Trump Memecoins Crash, Erode Billions In Investors&#8217; Wealth</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

$BTC

MSTR

MicroStrategy Drop 2.35% On Overnight Trading After Trump's Inauguration Speech Sidelines Cryptocurrency, Bitcoin Retreats Below $102K

Uniti intends to use the net proceeds of the offering to, among other things, repay and terminate its existing ABS bridge facility and for general corporate purposes, which may include success-based capital investments and/or repayment of outstanding debt.

UNIT

Reported Friday, Uniti Group Prices $589M Fiber Securitization Notes Secured By Florida And Gulf Coast Assets With 2030 Repayment Target

EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) reported quarterly losses of $(2.80) per share. This is a 53.33 percent increase over losses of $(6.00) per share from the same period last year. The company reported $21.10 million in sales this quarter. This is a 32.53 percent increase over sales of $15.92 million the same period last year

EZGO

Reported Friday, EZGO Technologies FY EPS $(2.80) Up From $(6.00) YoY, Sales $21.10M Up From $15.92M YoY

<ul>
<li>First approval in the U.S. for Daiichi Sankyo and AstraZeneca's DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy</li>
<li>Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo's DXd technology</li>
</ul>

DSNKY

Reported Friday, FDA Approves Daiichi Sankyo And AstraZeneca's DATROWAY AS A New Treatment Option For HR Positive, HER2 Negative Breast Cancer In The U.S.

Wells Fargo analyst Larry Biegelsen has assigned their bullish stance on NVCR stock, giving a Buy rating yesterday. Larry Biegelsen's rating is bas...

NovoCure's PANOVA-3 Trial Success Boosts Oncology Prospects

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

Piper Sandler raised the firm's price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the c...

Novocure price target raised to $42 from $28 at Piper Sandler

Evercore ISI raised the firm's price target on Novocure (NVCR) to $46 from $34 and keeps an Outperform rating on the shares. In the firm's 2025 out...

Novocure price target raised to $46 from $34 at Evercore ISI

SA Asks: Which biotechs are most likely to be acquired near-term?

Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?

Cash, cash equivalents and short-term investments were $959.9M as of December 31, 2024. Novocure (NVCR) reported preliminary unaudited financial an...

Novocure sees Q4 revenue $161.3M, consensus $153.05M

The company said 2024 growth was primarily driven by its launch in France and improved approval rates in the U.S., which are now reflected in its r...

Novocure sees FY24 revenue $605.2M, consensus $596.95M

Novocure anticipates higher-than-expected 2024 revenues

Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains t...

NovoCure's Strong U.S. Revenue and European Growth Reinforce Buy Rating Despite Mixed Regional Performance

BIIB

CRSP

GILD

GPCR

MDGL

MRNA

NVCR

QURE

REGN

SAGE

SMMT

SRPT

SRRK

TERN

VKTX

VRTX

Press Releases

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Novocure Reports Third Quarter 2024 Financial Results

Novocure Appoints Christoph Brackmann as Chief Financial Officer

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure to Participate in Upcoming Investor Conferences

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Comments

NovoCure

ニュース

最新ニュース NovoCure (NASDAQ:NVCR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル